Disease Info Card

Combined Hyperlipidaemia

Information about Combined Hyperlipidaemia: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Combined Hyperlipidaemia

Most recent studies have shown that Combined Hyperlipidaemia shares some biological mechanisms with arteriosclerosis, atherosclerosis, cardiovascular-diseases, coronary-artery-disease, coronary-heart-disease, diabetes-mellitus, diabetes-mellitus-non-insulin-dependent, dyslipidemias, heart-diseases, hypercholesterolemia, hypercholesterolemia-familial, hyperlipidemia, hyperlipidemia-familial-combined, hyperlipoproteinemia-type-iib, hyperlipoproteinemia-type-iv, hyperlipoproteinemias, hypertensive-disease, insulin-resistance, lipid-metabolism-disorders, obesity.

Among the many pathways, these few ones have gauged particular interests from scientists studying Combined Hyperlipidaemia, and have been seen in publications frequently: Aging, Blood Coagulation, Cell Adhesion, Cholesterol Efflux, Cholesterol Transport, Coagulation, Excretion, Fatty Acid Oxidation, Fibrinolysis, Gallstone Formation, Glucose Homeostasis, Insulin Secretion, Lipid Homeostasis, Lipid Oxidation, Lipoprotein Oxidation, Pathogenesis, Reverse Cholesterol Transport, Secretion, Transport, Vasodilation

Quite a number of genes have been found to play important roles in Combined Hyperlipidaemia, such as APOA1, APOA2, APOB, APOC3, APOE, C3, CD55, CETP, HES1, INS, LCP1, LDLR, LIPC, LPA, LPL, TCN2, TG, USF1. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.